CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
GT Medical Technologies
GT Medical Technologies logo

GT Medical Technologies

GT Medical Technologies: Innovating surgical radiation therapy for brain tumor treatment in the US.

Tempe, AZ, US🇺🇸
Founded
2017
Overview
Compare
Fundraising
Employees
Library

GT Medical Technologies focuses on innovating surgical radiation therapy for brain tumor treatment in the US. They offer GammaTile Therapy, a surgically targeted radiation therapy (STaRT) placed by neurosurgeons during resection. This therapy aims to delay tumor recurrence, extend survival, and minimize radiation exposure to healthy tissue, reducing side effects like hair loss.

GT Medical Technologies has made significant strides in the medical field by ensuring 100% treatment compliance and reducing the treatment burden for patients and caregivers. Their impact is reflected in improved patient outcomes and enhanced quality of life for those battling brain tumors.

GT Medical Technologies - Similar Companies

GT Metabolic Solutions logo

GT Metabolic Solutions

gtmetabolic.com

G-Tech Medical logo

G-Tech Medical

gtechmedical.com

Accuray logo

Accuray

accuray.com

Brainlab logo

GT Medical Technologies - Quick Facts

Who are GT Medical Technologies' competitors?

Companies similar to GT Medical Technologies include GT Metabolic Solutions, G-Tech Medical, Accuray and Brainlab.

When was GT Medical Technologies founded?

GT Medical Technologies was founded in 2017.

Where is GT Medical Technologies' headquarters located?

GT Medical Technologies' headquarters is located in Tempe, AZ, US.

When was GT Medical Technologies' last funding round?

GT Medical Technologies' most recent funding round was for $45M (USD) in March 2023.

How much disclosed funding has GT Medical Technologies raised?

GT Medical Technologies - Classification

Industry
  • Hardware
Ownership
  • Private
  • Venture-backed
Technology
  • Biotech

As of Mar 23, 2023, GT Medical Technologies has disclosed funding of $74M (USD). Undisclosed round amounts are excluded.

How many employees does GT Medical Technologies have?

GT Medical Technologies has 79 employees as of Feb 5, 2024.

Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 7 more industry codes
NAICS
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified

Brainlab

brainlab.com

Elite Health Systems logo

Elite Health Systems

usneuro.com

ViewRay logo

ViewRay

CranioVation logo

CranioVation

Cerebrotech Medical Systems logo

Cerebrotech Medical Systems

Gamma Therapeutics logo

Gamma Therapeutics

Jan Medical logo

Jan Medical

janmedical.com

GT Urological logo

GT Urological

gturo.com

Tiumed logo

Tiumed

Galaxy Therapeutics logo

Galaxy Therapeutics

Checkpoint Surgical logo

Checkpoint Surgical

Alpheus Medical logo

Alpheus Medical

alpheusmedical.com